Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe
PUURS, Belgium March 9 (Reuters) – U.S. drugmaker Pfizer (PFE.N) is ready to launch its respiratory syncytial virus (RSV) vaccine for both older adults and pregnant women in the United States and Europe later this year, executives said on Thursday.
Both Pfizer and British drugmaker GSK (GSK.L) have RSV vaccines they hope to launch in the United States and Europe this year, pending regulators’ approval.
“We are anticipating approval in both the U.S. and Europe in time for rollout in the fall,” Kena Swanson, Pfizer head of viral vaccines research & development, told a media briefing at the company’s biggest manufacturing and packaging site globally.
Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe | Reuters